Lung cancer drug alectinib put to the test in Dose-Finding trial
NCT ID NCT05713006
First seen Apr 22, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This study is testing the drug alectinib in 45 Mexican patients with advanced ALK-positive non-small cell lung cancer. In the first phase, patients receive increasing doses every 21 days to measure drug levels and safety. In the second phase, the chosen dose is given to see how well it shrinks tumors. The goal is to find the best dose for this population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE IIIB are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Thoracic Oncology Unit and Personalized Medicine Laboratory, Instituto Nacional de Cancerología
RECRUITINGMexico City, Mexico City, 14080, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alectinib (Alecensa)
What this could lead to
If successful, this could help determine the optimal alectinib dose for ALK-positive lung cancer patients, potentially improving treatment outcomes.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply to all patients. Dose escalation may cause side effects, and the drug may not shrink tumors as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.